No ratings yet
Taught by or worked with Nizar? Your rating helps other students choose.
Dr. Nizar Jacques Bahlis is an Associate Professor of Medicine at the University of Calgary in the division of Hematology and Bone Marrow Transplantation and a member of the Arnie Charbonneau Cancer Institute. He received his Doctor of Medicine degree in 1995 from Saint Joseph University – French Faculty of Medicine in Beirut. Dr. Bahlis completed his internal medicine residency at the State University of New York in Syracuse, followed by a Hematology-Oncology fellowship at the University of Miami in Florida. He also completed a postdoctoral fellowship in cancer biology at the University of Miami under the mentorship of Dr. Lawrence Boise.
Dr. Bahlis’ clinical and laboratory research focuses on plasma cell dyscrasia, with particular interest in multiple myeloma genomics, single cell immune profiling, and the development of novel therapeutics. He has established a Myeloma Genome Sequencing Unit to identify novel druggable genomic alterations and mechanisms of drug resistance. His laboratory examines signaling pathways, genomic alterations, and genomic instability in multiple myeloma, including the role of the proteasome-ubiquitin pathway in DNA damage repair. Dr. Bahlis has received awards including the ASCO Young Investigator Award and research funding from agencies such as the Multiple Myeloma Research Foundation, the Leukemia and Lymphoma Society of Canada, the Alberta Cancer Foundation, the National Institutes of Health, the Terry Fox Foundation, and the Canadian Institutes of Health Research. His work has been published in peer-reviewed journals including the New England Journal of Medicine, Blood, Journal of Clinical Oncology, Leukemia, Molecular Cancer Research, and Clinical Cancer Research. He has served on the editorial board of Blood, on review panels of national and international funding agencies, the American Society of Hematology plasma cell dyscrasia scientific panel, and the International Myeloma Society education panel.
Explore the groundbreaking University of Calgary study revealing resistance mechanisms to GPRC5D immunotherapy in multiple myeloma, using Canada's largest relapsed patient cohort. Implications for future treatments.
Photo by Antoine Dautry on Unsplash
Photo by Chris Liverani on Unsplash
Photo by Peter Burdon on Unsplash
Photo by Andrii Zhuk on Unsplash
Photo by EESOFUFFZICH on Unsplash
Photo by Google DeepMind on Unsplash
Photo by Gabriele Malaspina on Unsplash
